Cochlear implant coverage
This article was originally published in The Gray Sheet
Executive Summary
CMS accepts Cochlear Corp. (Nucleus 24 contour implant system) request July 8 for consideration of expanded cochlear implant national coverage based on the firm's expanded labeling, granted by FDA in 2000. FDA allows implantation in patients with test scores of 50% or less, but CMS currently permits coverage for patients with demonstrated test scores of 30% or less. CMS requests that the public submit medical evidence and published literature detailing expanded use of cochlear implants in adults and children, patient selection criteria and the appropriate screening needed to qualify a patient for an implant. The agency expects to issue a decision by April 4, 2005...
You may also be interested in...
CMS Hears Earful From Supporters Of Cochlear Coverage Criteria Expansion
Advanced Bionics recommends that CMS tie coverage criteria for cochlear implants to FDA indications as an alternative to establishing specific cutoff criteria
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.